WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018089695) TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/089695    International Application No.:    PCT/US2017/060946
Publication Date: 17.05.2018 International Filing Date: 09.11.2017
IPC:
C07D 231/56 (2006.01), C07D 235/18 (2006.01), C07D 487/04 (2006.01), C07D 519/00 (2006.01), A61P 35/00 (2006.01), A61K 45/06 (2006.01)
Applicants: DYNAVAX TECHNOLOGIES CORPORATION [US/US]; 2929 Seventh Street, Suite 100 Barkeley, CA 94710 (US)
Inventors: CANDIA, Albert, Frederick, III; (US).
BERESIS, Richard, Thomas; (US).
COFFMAN, Robert, L.; (US)
Agent: KUZELKA, Jane; (US).
BANKO, Max; (US).
ARJOMAND, Mehran; (US).
AIKEN, Charity; (US).
AHN, Sejin; (US)
Priority Data:
62/421,140 11.11.2016 US
62/421,144 11.11.2016 US
Title (EN) TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE
(FR) COMPOSÉS ANTAGONISTES DU RÉCEPTEUR DE TYPE TOLL ET LEURS MÉTHODES D'UTILISATION
Abstract: front page image
(EN)The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such as TLR7, TLR8 and/or TLR9 that are useful for inhibiting immune response and treating diseases associated with undesirable immune response.
(FR)L'invention concerne des composés de formule (I) : ou un sel ou solvate de ceux-ci, les variables étant telles que décrites dans la description. Les composés de formule (I) et les compositions pharmaceutiques de ceux-ci sont des antagonistes de récepteurs de type toll tels que TLR7, TLR8 et/ou TLR9 qui sont utiles pour inhiber la réponse immunitaire et traiter des maladies associées à une réponse immunitaire indésirable.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)